valuat
rais pt follow strong
result management continu execut well lead
highli anticip simparica trio launch project
compound-annual-growth-rate revenue ep
adjust estim reflect greater invest spend rais
revenue annual higher sg assumpt drove ep
high end management rang ep
estim revis figur vs consensu
rais pt increas pt old
ep new ep new valuat multipl
high end histor rang see exhibit assign
higher valuat due solid execut stellar track record
beaten consensu ep ten consecut quarter revenu growth
combo flea/tick/heartworm coverag reinvest new driver
diagnost refer lab extend durat growth
management continu expect fda approv simparica trio march follow
launch week approv management reiter complet
technic section simparica trio us packag submiss
current administr review await final approv separ
expect begin launch simparica trio europ phase approach
month management continu expect increment simparica/trio
franchis revenu
perspect margin prospect beyond management state
gross margin benefit fx tailwind bp gm
expect suffer bp fx headwind recently-acquir refer lab
diagnost busi lower gross margin off-set mix
favor come companion anim growth said margin
acquir busi expand leverag commerci
infrastructur ultim management see oper margin diagnost
come close core portfolio om regard simparica trio
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
impact margin management convey trio expect mildli benefici
overal gross margin increasingli benefici product
scale time
base case ep target multipl high end histor rang given
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
bull case ep
growth project zoeti pursu
growth project zoeti pursu
exceed expect organ ep upsid
plu upsid yield ep
forecast bring new growth
driver enhanc compani
durat growth
base case ep
driven growth key companion anim
driven growth key companion anim
product forecastingcagr revenu
growth ep compound-annual-growth-rate
annual global roll-out new
product give us condenc
zoeti combin compel
convers balanc rel high stock
growth ep growth
develop tuck-in apotenti
pressur new product disappoint
view descript risk reward theme
bear case ep
face lower end-market growth greater
face lower end-market growth greater
nancial result fda surprisingli
approv simparica trio march
approv without puppi claim zoeti
face new competitor key companion
price-to-earnings multipl contract
expect complet review end launch
simparica trio us launch exp earli eu canada
quarterli result guidanc updat
zoeti becom activ deploy capit
acquir products/compani
competitor could launch product
compet directli key zoeti growth driver
china india
view explan region hierarchi
research highest favor quintil
upsid quarterli result guidanc
margin expans expect
competitor perform wors anticip
new product approv delay launch
competit threat key product emerg
environment econom issu drivezoeti
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
